Endocrine Abstracts

Chemotherapy has historically been the ‘work horse’ of medical oncology. An improved understanding of the biological behavious of neuroendocrine neoplasms has led to decision-making based on pathological characterisation of neuroendocrine neoplasms in to well-differentiated neuroendocrine tumours (NETs) vs poorly-differentiated neuroendocrine carcinomas (NECs). Platinum/etoposide has an established role in high-grade NECs with high responses, although these are often...

Neuroendocrine tumours (NETs) are a heterogeneous, uncommon tumours for whom there have been few practice-changing clinical studies. Sub-groups of patients may be defined by site of origin, histological sub-type, mitotic activity and evidence of disease progression.Chemotherapy is active in patients with advanced pancreatic NETs; however, benefits are modest and associated with significant (albeit manageable) toxicity. Additional treatment options are sp...

Introduction: Platinum-etoposide chemotherapy is a globally established chemotherapy combination for EP-G3-NEC. However, there are many different schedules for such chemotherapy, and the preferred one for EP-G3-NEC has not been established.Methods: An international survey was created, and completed by colleagues with an expertise in the field of neuroendocrine neoplasms. The aim was to explore which schedules of platinum-etoposide chemotherapy are used a...

Background: New nuclear medicine imaging techniques have improved diagnosis, staging and treatment planning for BC. 68Ga-DOTA PET is preferable to standard somatostatin receptor scintigraphy where available (ENETS guidelines); however, its role in the management of BC remains unclear.Methods: All consecutive patients diagnosed with BC from two ENETS Centres of Excellence were identified retrospectively; patients with high grade tumours or lack...

Background: In patients with advanced GEPNETs, psychological symptoms may result due to potential disturbances in biogenic amines, particularly serotonin. This study compared HRQoL, anxiety, depression, and impulsivity in patients with and without carcinoid syndrome (CS) and correlated with serum 5-HIAA.Methods: Consecutive patients with advanced GEPNETs (with liver metastases) receiving treatment, with and without CS completed (single time-point) HRQoL ...

Background: Neuroendocrine tumours (NETs) are often associated with SPMs. This study aimed to identify SPMs in patients with non-pulmonary wdNETs.Methods: Patients seen at The Christie with non-pulmonary wdNETs from 2003–2017 were included. After exclusion of patients with hereditary predispositions, notes were retrospectively reviewed for location, functionality, treatment and temporal relation to diagnosis.Results: Of 854 pa...

Introduction: Platinum-etoposide is considered standard-of-care first-line treatment for patients diagnosed with advanced EP-PD-NECs. The optimal platinum-etoposide schedule remains undefined; carboplatin is often substituted for cisplatin, although quality data is lacking.Methods: Electronic records of patients with advanced EP-PD-NEC treated with carboplatin-etoposide (06/09-02/17) were reviewed retrospectively, with aim to provide real-life efficacy/s...

Background: Bone metastases (BMs) are rare in neuroendocrine neoplasms (NENs). There is no global consensus on the optimal management, and treatment is often extrapolated from experience in other tumour groups. The aim of this study was to review the current management and outcomes of patients with BMs in NENs.Method: A retrospective study was performed of all patients with NENs, except G3 lung NENs, treated at a tertiary centre from April 2002–Marc...

Background: Neuroendocrine tumours (NETs) are a rare and heterogeneous group of neoplasms that mainly originate from the gastroenteropancreatic tract (GEP-NETs). The vast majority of NETs tend to overexpress somatostatin receptors (SSTRs), which can be targeted by somatostatin analogues (SSAs). 68Gallium DOTA SSTR peptide positron emission tracer computed tomography (68Ga PET-CT) has emerged as superior to other imaging modalities in identifying SSTRs. Th...

Introduction: MANEC is a rare diagnosis and little is known on its epidemiology/prognosis/management.Methods: Demographic/clinical-pathological/survival data of patients with a diagnosis of MANEC (2010 WHO criteria) from five European centres were retrospectively reviewed.Results: Sixty-six patients were identified (09/80–07/17); median age: 62.5 years (range 34–89); male: 66.7%; ECOG-PS 0-1: 59%; primary tumours from: sm...